( Obstet Gynecol . 2025;145:286-296. doi: 10.1097/AOG.0000000000005825) Obesity involves excess body fat that produces pathogenic structural or functional abnormalities, and it is associated with increased morbidity and mortality. Estimates predict that by 2030, nearly 50% of Americans will be obese, including 40% to 45% of reproductive-aged women. Body mass index (BMI) is the most frequently used tool to diagnose obesity and estimate fat quantity, it does not account for the composition of adipose tissue; body fat distribution, ethnicity, race, and sex need to be accounted for when diagnosing obesity. Methods of estimating this in previous literature have included measurements of waist circumference, body roundness index, and waist/hip ratio. Previous literature has characterized the risks and negative effects on reproductive health that obesity can have, highlighting the importance of nuanced care for reproductive health in women with obesity. This article is a narrative review focusing on the literature surrounding the role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in managing reproductive health in patients with obesity.
Finkle et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: